The purpose is to determine whether the combination is safe and works better than the usual chemotherapy plus rituximab. Safety is evaluated by recording any adverse events (unwanted medical problems) and any dose‑limiting toxicity (a side effect that prevents increasing the dose). Effectiveness is judged by the rate of complete response, meaning all detectable cancer disappears, and by PFS, the length of time a person lives without the disease getting worse.

Participants receive the study medicines in repeated cycles that last a few weeks, with regular clinic visits for blood tests, imaging scans, and overall health checks. After the treatment period, they are followed for several years to watch for any return of the cancer and to continue safety monitoring. All data are collected confidentially and in accordance with standard clinical‑trial procedures.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients. Participants will receive either Zilovertamab Vedotin alone or together with Nemtabrutinib. Zilovertamab Vedotin is given as an injection into a vein, while Nemtabrutinib is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will take place over several weeks, during which participants will be closely monitored by healthcare professionals. They will undergo regular check-ups and tests to assess their response to the treatment and to ensure their safety. The study aims to provide valuable information that could lead to better treatment options for people with these types of blood cancers.

The purpose of this research is to determine how well patients respond to this combination treatment over a 12-month period. The medications work in different ways to target and destroy cancer cells – loncastuximab tesirine is an antibody-drug combination that delivers medication directly to cancer cells, while epcoritamab is a specialized antibody that helps the immune system recognize and fight cancer cells.

During the study, participants will receive both medications according to a specific schedule. Patients will have regular check-ups and imaging tests to monitor how their cancer responds to the treatment. The treatment period may last up to 54 weeks, depending on how well the patient responds and tolerates the medications. Throughout the study, doctors will closely monitor patients for any side effects or complications from the treatment.

The study will test if taking dapagliflozin while receiving standard lymphoma treatment can help prevent heart-related side effects. Participants will receive either dapagliflozin or placebo tablets for 6 months while undergoing their regular cancer treatment. The medication or placebo will be taken by mouth once daily.

During the study, doctors will monitor heart function using various tests to measure how well the heart is working. These tests include examining heart muscle movement, blood flow patterns, and checking certain substances in the blood that can indicate heart health. The study will also track any heart-related symptoms that participants may experience during their treatment.

The purpose of this study is to evaluate whether the combination of golcadomide and rituximab is more effective than other treatment options chosen by investigators for patients whose follicular lymphoma has not responded well to previous therapies. During the study, participants will receive either the combination treatment or another treatment selected by their doctor.

The study will track various outcomes including how long participants live without their disease getting worse, overall survival time, how well the cancer responds to treatment, and how the treatment affects quality of life. Participants must be over 18 years of age and meet specific health criteria to join the study.

The purpose of the study is to find out the highest concentration of these biotherapy drugs that can be used in skin tests without causing irritation in patients who are not allergic. The study will involve skin tests, such as prick tests and intradermal tests, to check for any allergic reactions. Patients who have been treated with these biotherapies and have not shown any allergic reactions will be part of the study. The study will monitor for any immediate or delayed skin reactions after the tests.

Throughout the study, patients will be contacted to confirm if there are any delayed reactions, which might occur up to a week after the skin tests. If a reaction is suspected, a photograph or video consultation with an allergist may be used to confirm it. The study aims to ensure that the skin tests are safe and do not cause unnecessary irritation to patients undergoing biotherapy treatments.

The purpose of the study is to evaluate how well these treatments work together in patients whose lymphoma has returned or has not responded to previous treatments. Loncastuximab Tesirine is an antibody-drug conjugate, which means it is designed to deliver a drug directly to cancer cells, while Epcoritamab is a bispecific antibody that helps the immune system target and destroy cancer cells. The study will involve administering these treatments to participants and monitoring their response over a period of time, up to 12 months, to see if the cancer shrinks or disappears.

Participants in the study will receive the treatments through injections, with Loncastuximab Tesirine given intravenously (through a vein) and Epcoritamab given subcutaneously (under the skin). The study aims to determine the best overall response rate, which includes both complete and partial remissions, and will also look at other outcomes such as progression-free survival and overall survival. The study will help researchers understand the potential benefits and risks of this combination therapy for patients with these types of lymphoma.

Participants in the study will be divided into groups based on their risk level. Those with high-risk disease will receive all three medications: rituximab, lenalidomide, and tafasitamab. Those with low-risk disease will receive rituximab and lenalidomide, with a chance of also receiving tafasitamab. The study will follow participants over a period to observe the effects of these treatments on their condition.

The trial aims to understand how these medications work together to treat follicular lymphoma and to monitor any side effects that may occur. The study will also look at how long the treatment effects last and how they impact the overall health and quality of life of the participants. This research is important for developing better treatment strategies for people with follicular lymphoma.

The purpose of this study is to evaluate the safety and effectiveness of this new treatment. Participants will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor how the body responds to the treatment and any side effects that may occur. The trial will also compare the new treatment to existing treatments to see if it offers any advantages.

In addition to HSP-CAR19M, other medications used in the study include Beneflur (containing fludarabine phosphate), Genoxal (containing cyclophosphamide monohydrate), RoActemra (containing tocilizumab), and Levact (containing bendamustine hydrochloride). These medications are used to prepare the body for the new treatment or to manage symptoms. Some participants may receive a placebo, which looks like the treatment but does not contain the active medicine. The study will continue until the end of 2025, with regular check-ups to assess the treatment’s impact on the cancer and the patient’s overall health.

The purpose of the study is to learn how well AZD0486 works and how safe it is for patients with this type of cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine will be given directly into a vein. The study will follow participants over time to see how their cancer responds to the treatment and to monitor any side effects they might experience.

Throughout the study, researchers will collect information on how the treatment affects the cancer and the overall health of the participants. This includes looking at changes in the size of the cancer, any improvements in symptoms, and any side effects that occur. The study aims to provide valuable information that could lead to new treatment options for people with Non-Hodgkin Lymphoma.

The purpose of the study is to see if the combination of Rituximab and Lenalidomide can improve the time patients live without the disease getting worse, known as progression-free survival. Participants in the study will receive either the combination treatment or Rituximab alone as maintenance therapy after their initial treatment. The study will last for up to 24 months, during which participants will be monitored regularly to assess the effectiveness and any side effects of the treatments.

This trial is designed for patients with Follicular Lymphoma who have experienced a return or worsening of their disease after previous treatments and are not eligible for a type of intensive treatment called autologous stem cell transplantation. The study aims to provide valuable information on whether the combination of Rituximab and Lenalidomide offers better outcomes compared to Rituximab alone, potentially leading to improved treatment options for patients with this condition.

The purpose of the study is to determine if reducing the number of chemotherapy cycles in patients who respond early to treatment is as effective as the standard full-dose therapy in terms of how long patients live without the disease getting worse, known as progression-free survival. The study will involve regular visits to the clinic for treatment and monitoring. Patients will receive the medications through different methods, such as injections or oral tablets, depending on the specific drug. The study will also include a placebo group to compare the effects of the actual medications against no active treatment. The trial will last for several months, with follow-up visits to assess the effectiveness and safety of the treatments.

Throughout the study, patients will be closely monitored for any side effects and overall health. The trial will also evaluate other outcomes, such as overall survival, which is the length of time patients live after starting the treatment, and the quality of life, which refers to the general well-being of the patients during and after the treatment. The study aims to provide valuable information on the best treatment approach for patients with high tumor burden Follicular Lymphoma, potentially leading to improved treatment strategies in the future.

The purpose of the study is to see if axicabtagene ciloleucel is more effective than the standard treatments in helping patients live longer without the cancer getting worse. Participants in the study will receive either the new treatment or one of the standard treatments. The study will monitor the progress of the disease and any side effects that may occur. The treatment will be given through an infusion, which means it is delivered directly into the bloodstream through a vein.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. The study aims to provide valuable information on whether axicabtagene ciloleucel can offer a better outcome for patients with relapsed or refractory follicular lymphoma compared to the current standard treatments. This research is important for developing new and improved ways to treat this type of cancer.

The study will test a medication called capivasertib (also known as TRUQAP) that comes in the form of film-coated tablets taken by mouth. Patients will receive either 160 mg or 200 mg tablets. This medication works by targeting specific processes that cancer cells use to grow and survive.

The main purpose of this study is to determine how well capivasertib works in treating these types of lymphoma by measuring how many patients show improvement after taking the medication. During the study, doctors will monitor patients’ responses to treatment through various medical examinations and imaging tests. They will also track how long any positive responses to the treatment last and evaluate the medication’s safety.

The purpose of the study is to find the best dose of Rapcabtagene Autoleucel and to understand its safety and effectiveness in treating these cancers. The study is divided into two phases. In the first phase, researchers aim to determine the appropriate dose and assess the safety of the treatment, both alone and in combination with Ibrutinib for CLL/SLL. The second phase focuses on evaluating how well the treatment works in reducing or eliminating the cancer. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study will also look at how the treatment affects the cancer over time. This research is important for developing new ways to treat these types of blood cancers and could lead to more effective therapies in the future.

The study is divided into multiple phases. In the first phase, researchers will determine the safe dose of tazemetostat when combined with the other medications. In later phases, patients will be randomly assigned to receive either tazemetostat or placebo along with lenalidomide and rituximab. Lenalidomide is taken as oral capsules, while rituximab is given through an intravenous infusion.

The treatment will continue for up to 12 months for lenalidomide, while rituximab will be given for up to 5 months. Throughout the study, researchers will monitor how well the treatment works and track any side effects that may occur. They will also assess how the treatment affects patients’ quality of life using specialized questionnaires.

The purpose of the study is to test the safety and feasibility of using CLIC-1901 CAR T-cell therapy in patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive the treatment through an intravenous infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor the effects of the treatment over a period of time to understand how well it works and to identify any side effects. The trial will also look at how the treatment affects the overall health and survival of the participants.

Throughout the study, researchers will keep track of various health indicators, such as the response of the cancer to the treatment, any side effects experienced, and the overall survival of the participants. The study aims to provide valuable information on the potential benefits and risks of using CAR T-cell therapy in treating these types of blood cancers. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.

Participants in this study will continue taking ibrutinib in the form of a hard capsule, which is taken orally. The study will monitor the long-term effects of ibrutinib and any potential side effects that may arise. Patients will be observed for any serious adverse events, which are significant health issues that may occur during the treatment. The study aims to ensure that patients who benefit from ibrutinib can maintain their treatment regimen and continue to manage their condition effectively.

The purpose of this study is to evaluate how safe and effective this new treatment is for patients whose cancer has returned or has not responded to previous treatments. The study will be conducted in two phases. In the first phase, researchers will determine the best dose of MB-CART19.1 to use. In the second phase, they will assess how well the treatment works in reducing cancer cells in the body. Throughout the study, participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Participants will receive the MB-CART19.1 treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study aims to find out if this approach can help control or eliminate the cancer, and how long any positive effects might last. The trial will also look at the overall health and survival of participants over time. Some participants may receive a placebo as part of the study to help compare the effects of the treatment. The study is expected to continue until the end of 2025.

The trial will investigate a new medication called Golcadomide (also known by its code name CC-99282), which is taken orally in capsule form. This medication will be tested both on its own and in combination with other treatments for NHL, including Rituximab, Obinutuzumab, Tafasitamab, and Valemetostat Tosylate. Rituximab is a monoclonal antibody, which is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. The purpose of the study is to determine the safety and tolerability of Golcadomide alone and in combination with these other treatments, as well as to find the best dose to use in future studies.

Participants in the study will receive the medication and be monitored for any side effects or changes in their condition. The study will also look at how the body processes the medication and its preliminary effectiveness in treating the disease. The trial is designed to gather important information that could lead to new treatment options for people with relapsed or refractory NHL.

Participants in the study will receive both Mosunetuzumab and Zanubrutinib. Mosunetuzumab is administered through an injection under the skin, known as subcutaneous use, and Zanubrutinib is taken orally as a capsule. The study will monitor the effects of these medications over a period of time to see how well they work in treating the lymphoma. Some participants may receive a placebo, which is a substance with no active medication, to compare the results.

The trial will follow participants to observe the response of their lymphoma to the treatment, including any changes in the size of the cancer and overall health outcomes. The study aims to provide valuable information on the potential benefits of combining these two treatments for people with relapsed or refractory follicular lymphoma. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather data on the effectiveness of the treatment combination.

Participants in the study will receive the treatment over several cycles. Each cycle involves taking the medications in a specific order and at specific times. The study will monitor how the body responds to the treatment and any side effects that may occur. The goal is to see if the treatment can lead to a complete response, meaning the cancer is no longer detectable at the end of the treatment period.

The study is divided into two phases. The first phase aims to find the most effective dose of Tazemetostat, while the second phase focuses on evaluating the treatment’s success in achieving a complete response in patients. The study will continue until the end of 2026, with the hope of providing valuable information on improving treatment options for patients with DLBCL and FL.

The purpose of the study is to compare how well these treatment combinations work in controlling the disease and to assess their safety. The study is divided into different parts, with some patients receiving Mosunetuzumab and Lenalidomide, and others receiving Rituximab and Lenalidomide. There is also a part of the study where all patients receive Mosunetuzumab and Lenalidomide without randomization. The study will monitor the patients over a period to see how the treatments affect the progression of the disease and to observe any side effects that may occur.

Throughout the study, patients will receive regular check-ups and assessments to track their response to the treatment. The study aims to provide valuable information on the best treatment options for managing follicular lymphoma, helping to improve outcomes for patients with this condition. The trial is expected to continue until 2029, allowing for comprehensive data collection and analysis.

The purpose of the study is to evaluate how well these treatments work when combined with a type of cancer treatment called radiotherapy, which uses high-energy rays to target and kill cancer cells. The study will compare the effects of standard-dose radiotherapy combined with Rituximab to low-dose radiotherapy combined with Obinutuzumab. Participants in the study will receive one of these treatment combinations, and their progress will be monitored over a period of time to see how the cancer responds.

Throughout the study, participants will undergo regular check-ups and imaging tests, such as CT scans, to assess the size and activity of the lymphoma. The study aims to determine which treatment combination is more effective in achieving a complete response, meaning the cancer is no longer detectable. The trial will also look at other factors, such as the side effects of the treatments and the overall quality of life of the participants during and after the study.

The purpose of the study is to evaluate how well tisagenlecleucel works in treating follicular lymphoma and to assess its safety. Participants in the study will receive the treatment and will be monitored over time to see how their cancer responds. The study will also track any side effects or adverse events that occur during the treatment period. The trial is designed to gather information on the complete response rate, which is the percentage of patients whose cancer completely disappears after treatment, as well as other outcomes like overall response rate and progression-free survival, which measures how long patients live without their disease getting worse.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the status of their lymphoma. These tests may include blood tests and imaging studies to see how the cancer is responding to the treatment. The study aims to provide valuable information on the potential benefits and risks of using tisagenlecleucel for treating follicular lymphoma, which could help improve future treatment options for this condition.

The purpose of the study is to see if adding Ibrutinib to Rituximab can help patients live longer without their disease getting worse, which is known as progression-free survival. Participants in the study will be randomly assigned to receive either the Ibrutinib and Rituximab combination or the placebo and Rituximab combination. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the effects of the treatment. The study will also look at other outcomes, such as the overall response rate, which measures how well the cancer responds to the treatment, and overall survival, which tracks how long participants live after starting the treatment. The trial aims to provide valuable information on whether the addition of Ibrutinib can improve outcomes for patients with Follicular Lymphoma.

The purpose of this study is to compare the effectiveness of the combination of Zanubrutinib and Obinutuzumab against using Obinutuzumab alone. Participants in the study will be randomly assigned to receive either the combination treatment or Obinutuzumab by itself. The study will monitor how well the treatments work in reducing the cancer and how long the effects last. Participants will receive treatment for a period of up to 30 days, and their response to the treatment will be evaluated by independent experts.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects from the treatments. The study aims to provide valuable information on whether the combination of Zanubrutinib and Obinutuzumab is more effective than Obinutuzumab alone in treating relapsed or refractory follicular lymphoma. This research could potentially lead to improved treatment options for patients with this type of cancer.

The purpose of this study is to determine if the combination of Epcoritamab, Rituximab, and Lenalidomide can improve the rate of complete response, meaning the disappearance of all signs of cancer, compared to the standard treatment known as chemoimmunotherapy. Participants in the study will be randomly assigned to receive either the new combination treatment or the standard treatment. The study will monitor participants over a period of time to assess the safety of the treatments and any changes in the activity of the disease. The study will also look at other outcomes, such as progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and overall survival, which is the length of time from the start of treatment that patients are still alive.

Throughout the study, participants will receive their treatments either through subcutaneous injection, which is an injection under the skin, or intravenous infusion, which is an injection into a vein, depending on the medication. The study aims to provide valuable information on whether this new combination of treatments can offer a better outcome for patients with previously untreated Follicular Lymphoma compared to existing treatment options. Participants will be closely monitored for any adverse events, which are any unwanted effects of the treatment, to ensure their safety throughout the study.

The purpose of this study is to compare the effectiveness and safety of the combination of Mosunetuzumab and lenalidomide against another treatment that uses an anti-CD20 monoclonal antibody along with chemotherapy. Participants in the study will receive either the new combination treatment or the standard treatment, which includes the anti-CD20 monoclonal antibody and chemotherapy. The study will help determine which treatment is more effective for patients with previously untreated follicular lymphoma.

During the study, participants will receive their assigned treatment and be monitored for their response to the therapy and any side effects they may experience. The study aims to provide valuable information that could improve treatment options for people with follicular lymphoma. The trial is expected to continue for several years to gather comprehensive data on the treatments being tested.

Participants in the study will receive either the new combination treatment or the standard treatment. The new combination involves mosunetuzumab, a type of cancer medicine that helps the immune system target cancer cells, and lenalidomide, which is another cancer medicine that works by affecting the immune system and stopping cancer cell growth. The standard treatment includes an anti-CD20 monoclonal antibody, which is a type of protein that targets specific cells, along with chemotherapy, which uses drugs to kill cancer cells. The study will monitor how well each treatment works in preventing the cancer from progressing and how safe they are for the patients.

The trial will take place over several years, with regular check-ups and assessments to track the progress of the disease and any side effects from the treatments. The study will help determine if the new combination of mosunetuzumab and lenalidomide is more effective than the current standard treatment for patients with untreated follicular lymphoma. This research is important for finding better ways to treat this type of cancer and improve the quality of life for those affected by it.

The purpose of the study is to determine the best dose of the combination treatment and to compare the two methods of administering Mosunetuzumab. The study will be conducted in two stages. In the first stage, participants will receive the combination of Mosunetuzumab and Lenalidomide to evaluate safety and determine the most suitable dose. In the second stage, participants will be randomly assigned to receive Mosunetuzumab either subcutaneously or intravenously, along with Lenalidomide, to further assess safety and how the body processes the drugs.

Throughout the study, researchers will monitor participants for any side effects and measure how the drugs are absorbed and processed by the body. The study aims to find out if the combination of Mosunetuzumab and Lenalidomide is a safe and effective treatment option for patients with Follicular Lymphoma.

The purpose of the study is to determine which combination works better in treating these types of lymphomas. Participants will be randomly assigned to one of the two treatment groups. The study will begin with a phase to ensure the safety and tolerability of the odronextamab and lenalidomide combination. Following this, the main phase will compare the two treatment combinations to see which is more effective in preventing the cancer from getting worse. This will be assessed by looking at how long participants live without their disease progressing, known as progression-free survival.

Throughout the study, participants will receive their assigned treatments and will be monitored regularly to assess the effects of the treatments and any side effects. The study is expected to last for several years, allowing researchers to gather enough information to make a clear comparison between the two treatment options. This research is important for finding better ways to treat follicular lymphoma and marginal zone lymphoma, potentially improving outcomes for patients with these conditions.

Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will monitor the participants over a period of time to see how their cancer responds to the treatment. This includes checking the levels of the modified immune cells in the blood and observing any changes in the cancer. The study will also look at the safety of the treatment by tracking any side effects that participants may experience.

In addition to Axicabtagene Ciloleucel, the study may involve other medications to support the treatment process. These include Tocilizumab, Dexamethasone, Fludarabine, Cyclophosphamide, Methylprednisolone, Diphenhydramine, Mesna, and Paracetamol. Some of these medications help manage side effects or enhance the effectiveness of the main treatment. The study aims to provide valuable information on how well this new treatment works and its potential benefits for patients with these types of lymphoma.

The purpose of the study is to determine if the combination of radiotherapy and Obinutuzumab can improve the time patients live without the disease getting worse, known as progression-free survival. Participants in the study will be randomly assigned to receive either radiotherapy alone or radiotherapy combined with Obinutuzumab. The study will follow participants over a period to observe the outcomes and gather data on the effectiveness and safety of the treatments.

Throughout the study, participants will receive regular check-ups and monitoring to assess their health and the progress of the treatment. The trial will help researchers understand whether adding Obinutuzumab to radiotherapy provides better results for patients with early-stage Follicular Lymphoma compared to radiotherapy alone. This research could potentially lead to improved treatment options for individuals diagnosed with this type of cancer.

The medications being tested are both types of targeted therapies. Mosunetuzumab is a specially designed antibody that helps the immune system recognize and attack cancer cells. Polatuzumab vedotin is a medication that combines an antibody with a substance that kills cancer cells. The study will test these medications given together through intravenous infusion or as an injection under the skin.

The study will check if this combination of medications is safe to use and how well it works in treating the lymphoma. Researchers will monitor patients for side effects and measure if the cancer responds to the treatment. The study will also look at how long any improvements last and how the medications move through the body. Additional medications may be given to help manage side effects, including prednisone, dexamethasone, paracetamol, and other supportive care medicines.

The purpose of the study is to see if adding tafasitamab to the treatment makes it more effective for patients whose cancer has returned or has not responded to previous treatments. Participants in the study will receive either the combination of tafasitamab, lenalidomide, and rituximab or a combination of lenalidomide and rituximab, along with a placebo. The study will monitor the participants over a period to see how well the cancer responds to the treatment and to check for any side effects.

Throughout the study, participants will receive the medications through different methods. Tafasitamab and rituximab are given as an infusion, which means they are delivered directly into the bloodstream through a vein. Lenalidomide is taken orally in the form of capsules. The study aims to provide valuable information on whether the addition of tafasitamab can improve treatment outcomes for patients with these types of lymphoma.

The purpose of the study is to explore how effective Mosunetuzumab is when used as a second-line treatment for patients whose follicular lymphoma has returned or worsened within 24 months after their first treatment. Participants in the study will receive Mosunetuzumab over a period of time, and their health will be monitored to see how the cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Mosunetuzumab.

The study will follow participants for a period of up to four years to observe their progression-free survival, which means the length of time during and after treatment that the cancer does not get worse. Other aspects being studied include the overall response rate to the treatment, the duration of response, and the safety and tolerability of Mosunetuzumab. The trial aims to gather important information that could help improve treatment options for people with follicular lymphoma in the future.